Ponatinib-d8

Description: Ponatinib D8 is a deuterium labeled Ponatinib. Ponatinib is an orally active inhibitor of multi-targeted kinase(Abl, PDGFRalpha, VEGFR2, FGFR1, and Src with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM, respectively). Smiles: [2H]C1([2H])N(C)C([2H])([2H])C([2H])([2H])N(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)C1([2H])[2H]. References: O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.